STOCK TITAN

Tyra Biosciences (NASDAQ: TYRA) taps Julia Rueb as principal accounting officer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Tyra Biosciences, Inc. named Julia Rueb, its Vice President of Finance, as the company’s principal accounting officer, effective April 1, 2026. She succeeds Chief Financial Officer Alan Fuhrman in this specific role, while he continues to serve as the company’s principal financial officer.

Rueb, age 40, has been Vice President, Finance since January 2024 and previously held senior accounting and controller roles at the company. Her background includes technical accounting and consulting positions at SOAProjects, van den Boom & Associates, and audit experience at Ernst & Young, primarily serving public life sciences companies.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Effective date of role change April 1, 2026 Date Julia Rueb became principal accounting officer
Julia Rueb age 40 Age of new principal accounting officer
VP Finance tenure start January 2024 Start of Julia Rueb’s role as Vice President, Finance
Ernst & Young tenure end October 2020 End of Rueb’s employment at Ernst & Young LLP
principal accounting officer financial
"designated Julia Rueb, Vice President, Finance of the Company, as the Company’s principal accounting officer"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
principal financial officer financial
"Mr. Fuhrman continues to be the Company’s principal financial officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Certified Public Accountant financial
"Ms. Rueb holds a Master’s degree in Accounting from the University of San Diego and is a Certified Public Accountant"
A certified public accountant (CPA) is a licensed accounting professional who has passed rigorous exams and met education and experience requirements to prepare, review, and officially certify financial statements and tax filings. For investors, a CPA's involvement is like a neutral referee confirming that a company's reported numbers are accurate and follow accounting rules, which improves trust in financial reports and lowers the risk of unexpected errors or misleading information.
false 0001863127 0001863127 2026-04-01 2026-04-01
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2026

 

 

Tyra Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-40800   83-1476348

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2656 State Street  
Carlsbad, California   92008
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (619) 728-4760

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   TYRA   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 
 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. (the Company) designated Julia Rueb, Vice President, Finance of the Company, as the Company’s principal accounting officer, succeeding Alan Fuhrman, the Company’s Chief Financial Officer, in that role, each effective as of April 1, 2026. Mr. Fuhrman continues to be the Company’s principal financial officer.

Ms. Rueb, 40, has served as Vice President, Finance of the Company since January 2024. Previously, Ms. Rueb served as Director and Senior Director of Accounting and Corporate Controller from October 2022 to December 2023. From October 2021 to October 2022, Ms. Rueb served as Associate Director and Director, Technical Accounting at SOAProjects, Inc. From October 2020 to October 2021, Ms. Rueb served as a Manager at van den Boom & Associates LLC, where she provided accounting and finance consulting services to various companies, primarily in the life sciences industry, including the Company. Earlier in her career, Ms. Rueb was employed at Ernst & Young LLP from 2013 to October 2020, most recently serving as an Audit Manager, where she primarily served public life sciences companies. Ms. Rueb holds a Master’s degree in Accounting from the University of San Diego and is a Certified Public Accountant. Ms. Rueb has no family relationships with any of the Company’s directors or executive officers.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      TYRA BIOSCIENCES, INC.
Date: April 2, 2026     By:  

/s/ Alan Fuhrman

     

Alan Fuhrman

Chief Financial Officer

FAQ

What leadership change did Tyra Biosciences (TYRA) announce on April 1, 2026?

Tyra Biosciences appointed Vice President of Finance Julia Rueb as its principal accounting officer, effective April 1, 2026. She replaces Chief Financial Officer Alan Fuhrman in that specific role, while he remains the company’s principal financial officer.

Does Alan Fuhrman remain CFO of Tyra Biosciences (TYRA)?

Yes, Alan Fuhrman continues as Tyra Biosciences’ Chief Financial Officer and principal financial officer. The change only shifts the principal accounting officer designation to Vice President of Finance Julia Rueb, effective April 1, 2026.

What is Julia Rueb’s background before becoming principal accounting officer at TYRA?

Before being named principal accounting officer, Julia Rueb served as Tyra’s Vice President, Finance since January 2024. She previously held controller and technical accounting roles and worked at SOAProjects, van den Boom & Associates, and Ernst & Young, mainly with public life sciences companies.

Does Tyra Biosciences (TYRA) disclose any family relationships for Julia Rueb?

The company states that Julia Rueb has no family relationships with any of Tyra Biosciences’ directors or executive officers. This disclosure supports governance transparency regarding potential related-party or nepotism concerns in senior finance appointments.

What qualifications does Julia Rueb bring to her new role at Tyra Biosciences (TYRA)?

Julia Rueb holds a Master’s degree in Accounting from the University of San Diego and is a Certified Public Accountant. Her experience spans corporate controller roles, technical accounting consulting, and audit work focused on public life sciences companies.

Filing Exhibits & Attachments

3 documents